Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Paratek Pharmaceuticals (NASDAQ:PRTK) and CareDx (NASDAQ:CDNA).
Paratek Pharmaceuticals (PRTK)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Paratek Pharmaceuticals today and set a price target of $55. The company’s shares closed yesterday at $9.24, close to its 52-week low of $9.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 20.9% and a 44.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Paratek Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $34.50.
See today’s analyst top recommended stocks >>
CareDx (CDNA)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on CareDx, with a price target of $22. The company’s shares closed yesterday at $25.73, close to its 52-week high of $29.60.
Selvaraju commented:
“Our price target is derived from a market value of the firm at $790M, which includes a discounted cash flow analysis based asset value of $803M for pre- and post-transplant tests, using a 15% discount rate and 2% terminal growth rate, excluding $13M debt and assuming 36.5M shares outstanding at the end of 3Q19.”
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of 5.0% and a 40.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CareDx with a $20 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
